Noble lessons from a kidney donor.

A. Al-Khader

2004-07-01

Saudi Journal of Kidney Diseases and Transplantation

Abstract:

What problem does this paper attempt to address?

Levonorgestrel-releasing Intrauterine System Effects on Metabolic Variables in PCOS.

Limei Ji,Lanying Jin,Ming Jun Shao,Min Hu,JIan Xu

DOI: https://doi.org/10.1080/09513590.2023.2208667

2023-01-01

Gynecological Endocrinology

Abstract:Background We aimed to determine and compare the reproductive hormone level and metabolic of patients with polycystic ovary syndrome (PCOS) when treated with a levonorgestrel-releasing intrauterine system (LNG-IUS). Objectives Sixty-four women with PCOS (Group A) and sixty-six healthy women inserted with a LNG-IUS for conception (Group B) were recruited from the Department of Obstetrics and Gynecology in Jinhua Hospital Zhejiang University School of Medicine. Method We compared the general characteristics of the cases between the two groups, including age, body mass index (BMI), systolic arterial pressure (SAP), diastolic arterial pressure (DAP), abdominal circumference (AC) and waist circumference (WC). Each patient was evaluated by transvaginal ultrasonography (TVS) to determine the number of oocytes and ovarian volume, and the intima-media thickness (IMT) of the common carotid artery was measured on an ECG image from the left common carotid artery before and six months, 12 months and 24 months after patients were inserted with the LNG-IUS. Hormone levels (follicle stimulating hormone, luteinizing hormone, serum estradiol and total testosterone), serum insulin, sex hormone binding globulin (SHBG), total cholesterol (TC), high density lipoprotein (HDL), and triglyceride (TG), were evaluated before and six months, 12 months and 24 months after patients were inserted with an LNG-IUS. The levels of testosterone (T) in the non-HA (hyperandrogenemia) group and HA group in PCOS group were compared with the baseline. We also compared cases without insulin resistance in the PCOS group with their baseline. Results Prior to LNG-IUS insertion, the PCOS group had significantly higher total testosterone levels (p < 0.05), lower HDL levels (p < 0.05), and a greater ovarian volume (p < 0.05) than the control group. Compared to baseline values, there was a significant increase in fasting glycemia at six months after LNG-IUS insertion (p < 0.05). Mean ovarian volume was significantly smaller than the volume prior to LNG-IUS insertion (p < 0.05); LDL and TC were significantly reduced when compared to baseline evaluation in the PCOS group. The remaining variables did not differ significantly during the 24 months follow-up period. The control group did not show any significant changes when compared to the period before LNG-IUS insertion. When the groups were compared after the 24-month follow-up, WC, AC, FSH, LH, T, SHBG, HDL, FINs, FAI and ovarian volume were significantly different when compared between the two groups (p < 0.05) . Conclusion The LNG-IUS is an effective and safe non-surgical device and the use of this system for 24 months did not result in significant changes in the clinical and metabolic variables in women with PCOS and healthy control females.
Molecular Systems Biology Peer Review Process File Genetic Variation in Insulin-induced Kinase Signaling Transaction Report

I. X. Wang,Girish Ramrattan,Vivian G Cheung

Abstract:(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.) Thank you again for submitting your work to Molecular Systems Biology. We have now heard back from the three referees who agreed to evaluate your manuscript. As you will see from the reports below, the referees raise substantial concerns on your work, which, I am afraid to say, preclude its publication in Molecular Systems Biology. While reviewer #1 is overall positive, reviewers #2 and #3 raise significant concerns regarding the analysis and interpretation of the data and they are not convinced about the validity of the main conclusions. Considering the substantial concerns raised and the overall low level of support provided by the referees, we have no choice but to return this manuscript with the message that we cannot offer to publish it. Nevertheless, since the referees did have positive words for the goals of this study, we would not be opposed to considering a revised and extended manuscript based on this work. Any new submission would need to include new experimental data and further analyses thoroughly addressing the concerns raised by the reviewers. Without repeating all the points listed below, among the most fundamental issues are the following:-The reviewers point out that the causal link between the SNPs and the observed variations in insulin response remains unclear, while alternative explanations need to be excluded. Importantly, reviewer #3 is concerned about the non-physiological doses of insulin used in the experiments, which could significantly affect the measured response.-As reviewer #2 indicates, a truly integrative analysis providing conclusive mechanistic links between genetic variation, signaling response and insulin-responsive gene expression is at present lacking. A resubmitted work would have a new number and receipt date. We recognize that this would
Factors Associated With the Use of U.S. Community-Based Palliative Care for Children With Life-Limiting or Life-Threatening Illnesses and Their Families: An Integrative Review.

J. Boyden,M. Curley,J. Deatrick,M. Ersek

DOI: https://doi.org/10.1016/j.jpainsymman.2017.04.017

IF: 5.576

Journal of Pain and Symptom Management

Abstract:
Intrauterine device use is safe among nulligravidas and adolescent girls

M Valeria Bahamondes,Luis Bahamondes

DOI: https://doi.org/10.1111/aogs.14097

Abstract:The use of intrauterine devices (IUDs), including the copper-bearing device and the levonorgestrel intrauterine system (LNG-IUS), is safe among nulligravidas and adolescent girls. However, several misconceptions limit their use in clinical practice; health-care providers are hesitant to prescribe IUDs, and several myths associated with their usage in nulligravidas and adolescents exist among both providers and women themselves. The high rates of unplanned pregnancies (which in many settings constitute a public health issue, primarily among adolescent females) can be attributed at least partially to lack of awareness and limited use of highly effective contraceptives such as IUDs. In this review, we discuss the role of non-hormonal and hormonal IUDs as effective contraceptives in nulligravidas and adolescent girls. We present a literature review of data that highlight contraceptive efficacy, side effects (including reasons for discontinuation), and continuation rates with the method. We searched the PubMed/MEDLINE, Cochrane Library, Embase, and Scopus databases for all articles published in English between January 1990 through September 2020. A large body of evidence confirmed the effectiveness of IUD/IUS, independent of age and parity. Studies showed a high expulsion rate among adolescents but not among nulligravidas. Additionally, bleeding patterns among adolescents and nulligravidas were similar to those observed among adults and parous women. The high early removal rates observed in adolescents were attributable to bleeding and/or pain, which indicate that compared with adults, adolescents are less likely to accept IUD-induced side effects. IUD placement is an excellent strategy to avoid the high rates of unplanned pregnancies in adolescents and nulligravidas. IUDs are more effective than short-acting reversible contraceptives with failure rates that are equivalent to those observed with permanent contraception. However, few long-term studies have investigated this category of women to definitively establish the role of IUD/IUS as effective means of contraception.
Production of a recombinant alkane hydroxylase (AlkB2) from Alcanivoraxborkumensis

Mandana Miri,B. Bambai,F. Tabandeh,M. Sadeghizadeh,N. Kamali

DOI: https://doi.org/10.1007/s10529-009-0177-0

2010-04-01

Biotechnology Letters

Abstract:
Levonorgestrel-releasing intra-uterine systems as female contraceptives

Giovanni Grandi,Antonino Farulla,Filomena Giulia Sileo,Fabio Facchinetti

DOI: https://doi.org/10.1080/14656566.2018.1462337

Abstract:Introduction: The availability and use of long-acting reversible contraceptives (LARCs), such as levonorgestrel intrauterine systems (LNG-IUSs), have increased in recent times. Areas covered: The authors provide a narrative review of the LNG-IUSs currently available worldwide as female contraceptives (LNG-IUS 13.5, 19.5 and 52 mg). Specific features of the devices and their parameters of efficacy and tolerability were considered as outcomes. Expert opinion: The one-handed 3.8-mm-diameter inserter of LNG-IUS 13.5 mg and 19.5 mg may be particularly suitable in nulliparous women. While LNG-IUSs 13.5, 19.5 mg and LNG 52 mg should be used by women simply looking for an effective contraceptive method for up to 3, 4 or 5 years, LNG-IUS 52 mg has also been approved for the treatment of heavy menstrual bleeding and endometrial protection during hormone replacement therapy. LNG-IUS 52 mg is ideal for women who are experiencing a certain hyperestrogenic hormonal environment, with heavy menstrual bleeding due to hormonal imbalances, adenomyosis or fibroids, in the case of symptomatic endometriosis or for endometrial protection during hormone estrogenic replacement therapy in non-hysterectomized women.
[Does desensitisation of acetylcholine receptors play a physiological role in the neuromuscular synapse?].

R. Giniatullin,L. Magazanik

Abstract:After the acetylcholinesterase inhibition, desensitisation of neuro-muscular junctions was found to limit rebundunt activity of postsynaptic membranes and disturb normal transmission. Long-term densensitisation of cholinoreceptors entails shortening of the postsynaptic current decay due, probably, to a high affinity binding the acetylcholine molecules to the desensitised receptors. This may prevent repetitive interactions with active receptors and buffer a certain amount of acetylcholine.
Early intrauterine pregnancy with an intrauterine device in place and terminated with spontaneous abortion: A case report

Yu-Qun Chu,Chin-Tzu Tien,Dah-Ching Ding

DOI: https://doi.org/10.1097/md.0000000000037843

IF: 1.6

2024-04-20

Medicine

Abstract:Rationale: The overall pregnancy rate in individuals with an intrauterine device (IUD) for contraception is <1%. If pregnancy occurs while an IUD is in place, there is a higher risk of an ectopic pregnancy. We report the case of a woman with an IUD who was 7 weeks pregnant and experienced a spontaneous abortion 1 week later. Patient concern: A 32-year-old woman presented to our outpatient department with intermittent vaginal staining for several days. Diagnoses: She was 7 weeks pregnant and had an IUD in place for over 4 years. A vaginal examination revealed no vaginal bleeding and no blood clots; however, a parous cervix was observed. The IUD string was not visible. Transvaginal ultrasonography revealed a gestational sac in the uterine cavity, with a fetal pole and a crown-rump length of 11.4 mm. The fetal heart rate was 159 beats/min. The IUD was located in the retroplacental region. The bilateral adnexa appeared normal (right ovary, 2.9 cm; left ovary, 2.5 cm). The patient was diagnosed with an intrauterine pregnancy with an IUD in place and threatened abortion. Interventions: Attempts to remove the IUD were abandoned due to its location, and conservative treatment was initiated with Utrogestan (100 mg) administered 3 times a day for 1 week. Bed rest was advised. Outcomes: Unfortunately, she experienced a complete abortion 1 week later. Lessons: The novelty of this case report lies in the rare occurrence of an intrauterine pregnancy with a long-term IUD in place, the challenges posed by the IUD's specific location, and the complex management of threatened abortion in this context. Our case highlights the diagnostic management approach for intrauterine pregnancy with an IUD in place. Furthermore, it explores the impact of IUD location on pregnancy prognosis.

medicine, general & internal
Levonorgestrel-Releasing Intrauterine Device Is An Efficacious Contraceptive For Women With Leiomyoma

Z.-W. Xie,Y.-N. Zhang,S. Wan,W.-Z. Xu,J. Chen

DOI: https://doi.org/10.1177/030006051204000538

2012-01-01

Journal of International Medical Research

Abstract:OBJECTIVE: To evaluate the efficacy of a levonorgestrel-releasing intrauterine device (LNG-IUD) as contraception for women with uterine leiomyoma. METHODS: Thirty women with uterine leiomyoma requiring contraception were enrolled and had a LNG-IUD inserted. Menstrual blood volume (assessed by a pictorial blood loss assessment chart [PBAC]), haemoglobin concentration, volume of uterus and leiomyoma were determined before and after LNG-IUD insertion. RESULTS: The median (range) PBAC score was 145.0 (60.0 - 232.0) before LNG-IUD insertion, which significantly decreased to 44.0 (0.0 - 99.0) and 36.0 (0.0 - 90.0) after 6 and 12 months of LNG-IUD use, respectively. Prior to LNG-IUD insertion, the median haemoglobin concentration in patients with anaemia was 100.0 (69.0 - 109.0) g/l and this increased significantly after 6 and 12 months of LNG-IUD use, to 117.5 (101.0 - 131.0) g/l and 119.5 (108.0 - 135.0) g/l, respectively. There were no significant changes in uterine or leiomyoma volumes. No patient became pregnant and there were no severe side-effects; one IUD was expulsed. CONCLUSION: The LNG-IUD may be a safe and effective contraceptive for women of reproductive age with uterine leiomyoma.
Acoustic signal recognition with a photorefractive time-delay neural network.

G. Zhou,D. Z. Anderson

DOI: https://doi.org/10.1364/OL.19.000655

IF: 3.6

1994-05-01

Optics Letters

Abstract:We present a photorefractive processor for audio-acoustic signal recognition based on the time-delay neural network model of Hopfield and Tank [in Neural Models of Plasticity, J. H. Byrne, ed. (Academic, New York, 1989), p. 363-377]. We demonstrate the recognition of three words by programming the interconnection weights of the time-delay network.
Preliminary report on the use of a levonorgestrel intrauterine system for the treatment of intermenstrual bleeding due to previous cesarean delivery scar defect

Ying‐Yi Chen,Ching‐Chang Tsai,Kuo‐Chung Lan,Yu‐Che Ou,Ying‐Yi Chen,Ching‐Chang Tsai,Kuo‐Chung Lan,Yu‐Che Ou

DOI: https://doi.org/10.1111/jog.14060

2019-08-05

Journal of Obstetrics and Gynaecology Research

Abstract:AimTo evaluate the efficacy of levonorgestrel intrauterine system (LNG‐IUS) treatment in patients with previous cesarean delivery scar defect (PCDS)‐related intermenstrual bleeding. MethodsA total of six premenopausal patients who experienced PCDS‐related intermenstrual bleeding were enrolled for conservative therapy with LNG‐IUS (levonorgestrel 20 μg/24 h) insertion. The durations of menstruation before and after LNG‐IUS insertion at 1, 6 and 12 months were recorded. A total of three missed menstrual cycles was defined as amenorrhea. Any side effects and the device expulsion rate were also recorded. Patient follow‐up was at an outpatient clinic. Any missing data were obtained by telephone. ResultsAt the start of the study the median duration of intermenstrual bleeding was 6.5 days (range 3–22 days). After 6 months treatment, two of the six patients had developed amenorrhea and two patients experienced cessation of vaginal spotting. One patient reported expulsion of the device. All patients except the one with device expulsion responded to the conservative treatment after 1 year. ConclusionThe findings of the current study support LNG‐IUS being effective for the treatment of PCDS‐related intermenstrual bleeding. The authors recommend LNG‐IUS as a treatment option for PCDS‐related intermenstrual bleeding.

obstetrics & gynecology
One-year follow up on post-placental IUD insertion: A randomized clinical trial

Marcos Marangoni Jr,Montas Laporte,Fernanda Surita,Maria B Kraft,Luis Bahamondes,Cássia R T Juliato

DOI: https://doi.org/10.1111/aogs.14081

Abstract:Introduction: Our objectives were to compare the 1-year follow-up clinical performance of the TCu380A intrauterine device (TCu380A-IUD) and levonorgestrel (LNG) 52-mg intrauterine system (IUS) inserted at post-placental period. Material and methods: We conducted an open-label, parallel-group, randomized clinical trial, 1:1 with pregnant women admitted for childbirth independently of the mode of birth. Our primary outcome was expulsion up to 1 year after device placement by type of IUD and mode of delivery. During the follow up (42, 90 and 365 days (±7 days) after device placement), an ultrasound was performed to evaluate the device position. Kaplan-Meier with log-rank test was used to compare the survival curves of the TCu380A IUD and the LNG IUS. Couple-Years of Protection after insertion of both devices was calculated. Results: One hundred and forty women were randomized to the TCu380A IUD (n = 70) or the LNG IUS (n = 70). By the end of the first year after device placement, 38 women experienced device expulsion (27.1%), most of them (33/38; 86.8%) within the first 42 days after delivery. The expulsions were significantly higher among users of TCu380A IUD (39.4%) than among users of the LNG IUS (22.2%; P = .039), and among those with vaginal delivery (43.8%) than among women with cesarean delivery (15%; P = .003). The 1-year cumulative continuation rate was 64.2%, significantly higher for LNG IUS (73.1%) than for TCu380A IUD (54.4%; P = .03), and among women with cesarean delivery (77.6%) than for vaginal delivery (52%; P = .00). The post-placental IUD insertion provided 356.4 Couple-Years of Protection. Conclusions: Two-thirds of women who accepted a post-placental IUD placement still used the device 1 year after childbirth. However, expulsion was the most prevalent reason for discontinuation, mainly within 42 days after device placement. The expulsion rate was significantly higher among TCu380A IUD users and among women with vaginal delivery.
Levonorgestrel Intrauterine Device Use in Overweight and Obese Women

Lynne Y Saito-Tom,Reni A Soon,Sara C Harris,Jennifer Salcedo,Bliss E Kaneshiro

Abstract:The levonorgestrel intrauterine device (LNG-IUD) is a safe, effective, long-acting, reversible contraceptive that reduces unintended pregnancy and decreases heavy menstrual bleeding. Many procedures such as IUD insertion are more challenging in overweight and obese women. The objective of this study was to describe LNG-IUD insertion, continuation, and complications in overweight and obese women in an ethnically diverse population in Hawai'i. A retrospective cohort study of women who had a LNG-IUD inserted at the University of Hawai'i, Department of Obstetrics and Gynecology Resident and Faculty practice sites between January 2009 and December 2010 was performed. A total of 149 women were followed. The most commonly reported races were Asian (32%), Native Hawaiian (26%), and non-Hawaiian Pacific Islander (20%). The mean BMI of the study population was 28.4 (standard deviation 7.2) with 37% classified as normal weight, 30% as overweight, and 33% as obese. Overall, 76% of women continued the LNG-IUD 12 months after insertion. No statistically significant difference emerged in 12-month IUD continuation between the BMI groups. Difficult (5%) and failed (3%) IUD insertions were rare for all BMI groups. IUD complications occurred in 9% of women and included expulsion and self-removal. In this diverse population, the majority of women continued to use the LNG-IUD one year after insertion with low rates of difficult insertions and complications.
Postplacental placement of intrauterine devices: A randomized clinical trial

Montas Laporte,Marcos Marangoni Jr,Fernanda Surita,Cassia T Juliato,Mariana Miadaira,Luis Bahamondes

DOI: https://doi.org/10.1016/j.contraception.2019.12.006

IF: 3.051

Contraception

Abstract:Objective: To compare the expulsion rate of the TCu380A intrauterine device (IUD) or levonorgestrel (LNG) 52 mg intrauterine system (IUS) up to 90 days after postplacental placement (10 min after delivery of the placenta). Study design: Randomized trial (1:1) of women aged 18-43 years and ≥37 weeks pregnant enrolled during early or prodromal labor at the University of Campinas, Brazil. Follow-up was scheduled at 42 and 90 days after device placement. We confirmed the IUD or IUS location using ultrasonography. Multivariate logistic regression was used to assess variables associated with expulsion. Results: We enrolled 140 women, and assigned 70 to the TCu380A IUD and 70 to the IUS groups. By the 90-day follow-up visit, 22/60 women (36.7%) in the TCu380A IUD group had expelled the device, as had 12/60 women in the IUS group (20%). Thirty-three of the 34 expulsions had occurred by the 42-day visit. Multivariate analysis demonstrated that the expulsion odds ratio ([OR]; 95% confidence interval [CI]) was higher after vaginal delivery than after Cesarean delivery (OR 5.60; 95% CI 2.08-15.10; P < 0.00) and higher among women with one (OR 4.38; 95% CI 1.33-14.43; P 0.00) or three or more deliveries (including the present one) (OR 6.08; 95% CI 1.78-20.77; P 0.00) than those with two deliveries. Conclusions: Postplacental TCu380A IUD placement had a higher expulsion rate than the IUS, and the expulsion rate was higher among women who had a vaginal delivery than those who had a Cesarean delivery. Most of the expulsions occurred within 42 days. Implications: Policy makers should increase the availability of both the TCu380A and the LNG intrauterine devices for the immediate postpartum period, even though the expulsion rate is higher than that after interval placement.
Unilateral hydroureteronephrosis after introduction of a levonorgestrel-releasing intrauterine system: a case report and literature review

Francesco G Martire,Matteo Giorgi,Luca Labanca,Gabriele Centini,Francesco Catania,Caterina Exacoustos,Errico Zupi,Lucia Lazzeri

DOI: https://doi.org/10.23736/S2724-606X.22.05112-0

Abstract:Insertion of a LNG-Intra-uterine System (LNG-IUS) has many gynecological indications. The approved indications worldwide are contraception, treatment of abnormal uterine bleeding depending on not organic disease, and endometrial protection in case of an estrogenic therapy. Instead adenomyosis, fibroids, and fertility-sparing management of endometrial hyperplasia or early endometrial cancer in patients with desire of pregnancy are off label indications. Hydroureteronephrosis is an uncommon complication during LNG-IUS insertion. There are few cases described in the literature. The first diagnostic approach for this complication is an abdominal-pelvic ultrasound scan to identify the abnormal position of the device. Diagnostic management includes computed tomography (CT) or magnetic resonance imaging (MRI), which are necessary to confirm hydroureteronephrosis and to assess the exact location of the LNG-IUS in the abdomen. A minimally invasive approach is the standard of care with the removal of the device, while the therapeutic management of the hydroureteronephrosis depends on ureteral and kidney involvement. We report the history of a dislocated LNG-IUS in the left paracervical space with subsequent ipsilateral hydroureteronephrosis. In our case we removed the device through hysteroscopy and later inserted a J-J stent. Follow-up at three months revealed the persistence of left hydroureteronephrosis, so we performed ureter reimplantation. We also performed a review of the literature to analyze common diagnostic and therapeutic pathways for this rare complication.
Newborn immunology: relevance to the clinician.

D. Lewis,J. Gern,H. Hill,S. Friedlander,T. R. La Pine,R. Lemanske,E. Stiehm

DOI: https://doi.org/10.1016/J.CPPEDS.2005.11.001

IF: 2.557

2006-05-01

Current Problems in Pediatric and Adolescent Health Care

Abstract:
[Efficacy and Safety of Low-Dose Levonorgestrel-Releasing Intrauterine System in Chinese Women: a Multicenter, Single-Arm, Open Labeled Interventional Trial].

C F Qian,G S Fan,Q P Liao,S Y Wu,D,W Di,B H Dong,H W Liu,L D Tang,Z A Xiong,H W Zhang,Y L Hu,N M Yang,M L Ren,H Shi,G P Deng,Z R Huang

DOI: https://doi.org/10.3760/cma.j.issn.0529-567x.2018.06.009

2018-01-01

Abstract:Objective: To evaluate the efficacy, bleeding profile and safety of low-dose levonorgestrel-releasing intrauterine system (LNG-IUS 8) in Chinese healthy women of childbearing age. Methods: A multi-center, open-label, single-arm clinical trial conducted at 16 centres in China enrolled 773 healthy women of childbearing age (mean age 31.6 years old, range 18 to 40 years old) , who demanded contraception, from April 2006 to June 2013. All women placed LNG-IUS 8 for 3 years and then been followed up at 3, 6, 9, 12, 18, 24, 30, 36 months. The efficacy variables including pregnancy rate and expulsion rate were analyzed using life table, while observing adverse events (AE) to evaluate the safety. The bleeding profile happened during the study was assessed using 90-day reference intervals (World Health Organization criteria) . Results: Eight pregnancies occurred among 773 women, resulting in a overall Pearl index of 0.42 per 100 women years. The 3-year cumulative pregnancy rate was 0.37 per 100 women years and the 3-year cumulative expulsion rate was 1.99 per 100 women years. The number of women with bleeding/spotting reduced and the bleeding/spotting days declined over time. Totally 219 AE were reported related to LNG-IUS 8 placements. The most common AE were vaginal bleeding (8.2%, 63/773) and the ovarian cyst (6.2%, 52/773) . LNG-IUS 8 had an improving effect on dysmenorrhea that the percentage of women with dysmenorrhea as well as the days of dysmenorrhea decreased over time. The percentage of women satisfied or very satisfied with LNG-IUS 8 was 87.2% (622/713) . Conclusion: LNG-IUS 8 is highly effective and safe for Chinese healthy women of childbearing age.
Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study

Umberto Leone Roberti Maggiore,Fabio Martinelli,Giulia Dondi,Giorgio Bogani,Valentina Chiappa,Maria Teresa Evangelista,Viola Liberale,Antonino Ditto,Simone Ferrero,Francesco Raspagliesi

DOI: https://doi.org/10.3802/jgo.2019.30.e57

2019-01-01

Journal of Gynecologic Oncology

Abstract:OBJECTIVE: To investigate the efficacy of levonorgestrel-releasing intra-uterine system (LNG-IUS) treatment in patients affected by atypical complex hyperplasia/endometrial cancer (ACH/EC) wishing to preserve their fertility and to present fertility outcomes of those patients who actively tried to conceive.METHODS: Data of consecutive women with ACH/EC who underwent fertility-sparing treatment using LNG-IUS were retrospectively evaluated.RESULTS: Overall, 48 patients and the mean (±standard deviation) length of follow-up was 82.6±47.2 months. Among patients with ACH, 25/28 (89.3%) had a complete response (CR), 2/28 (7.1%) had a partial response (PR) and 1/28 (3.6%) had a progressive disease (PD). Mean (±standard deviation) time to CR was 6.7±4.0 months. Among patients with G1 EC, 13/16 (81.3%) had a CR, 1/16 (6.3%) had a PR and 2/16 (12.5%) had a PD. Mean (±standard deviation) time to CR was 5.0±2.9 months. Among patients with G2 EC, 3/4 (75.0%) had a CR and 1/4 (25.0%) had a PD. Mean (±standard deviation) time to CR was 4.0±0 months. Only 19 (39.6%) patients who had CR actually attempted to conceive. Eleven (57.9%) women tried to conceive naturally while 8 (42.1%) women underwent an in vitro fertilization (IVF). Fourteen (73.7%) patients wishing to conceive achieved a pregnancy (6 spontaneously and 8 through IVF).CONCLUSIONS: Fertility-sparing treatment of patient with ACH/EC with LNG-IUS achieves high regression rates and good fertility outcomes. Future larger multi-institutional studies should be designed to confirm these preliminary findings.

oncology,obstetrics & gynecology
Towards successful user interaction with systems: focusing on user-derived gestures for smart home systems.

Eunjung Choi,Sung-hyuk Kwon,Donghun Lee,Hogin Lee,M. Chung

DOI: https://doi.org/10.1016/j.apergo.2014.02.010

IF: 3.94

2014-07-01

Applied Ergonomics

Abstract:
Bleeding Pattern Difference Between Levonorgestrel Intrauterine System and Copper Intrauterine Devices Inserted Immediately Post-Abortion: a Multicenter, Prospective, Observational Cohort Study in Chinese Women.

Xiaoning Chen,Qianxi Li,Xiaoye Wang,Jing Chen,Wen Lv,Bin Shi,Hong Wang,Jianru Luo,Jian Li

DOI: https://doi.org/10.1080/03007995.2017.1421919

2018-01-01

Abstract:Background: To describe the bleeding pattern (primary outcome), side effects, treatment satisfaction and 6 month continuity rates associated with the 52 mg levonorgestrel intrauterine system (LNG-IUS) and the copper intrauterine device (Cu-IUD) inserted immediately after abortion. Methods: This multicenter, prospective, observational cohort study enrolled healthy women (aged 18 years) inserted with LNG-IUS or Cu-IUD immediately after first-trimester surgical abortion and followed up to 6 months. Bleeding pattern was obtained through daily patient bleeding diaries. Results: From 2013 to 2014, we enrolled 512 women (LNG-IUS = 312 [median age: 32.0 years] and Cu-IUD = 200 [median age: 30.0 years]) from nine Chinese centers. LNG-IUS resulted in a significantly lower number of bleeding/spotting days in the second 90 day reference period compared with Cu-IUD (median 14.5 vs. 18.0 days, p < .0001). Amenorrhea rate (no bleeding/spotting day in the second 90 day reference period) and no menstrual bleeding rate (absence of bleeding days in the second 90 day reference period) were significantly higher in LNG-IUS compared to Cu-IUD (13.9% vs. 0% and 39.5% vs. 0%; p < .001 for all). No dysmenorrhea was higher at the last follow-up in LNG-IUS users than Cu-IUD users (81.2% vs. 76%; p = .0047). Both treatments had a high satisfaction rate among women at both the follow-up visits, and the majority of them continued with the treatment. The rates of adverse events (e.g. oligomenorrhea, amenorrhea) in the LNG-IUS and Cu-IUD groups were 77.2% and 44.5% (p < .0001), respectively. Conclusion: LNG-IUS post-abortion shows better bleeding patterns, and reduced dysmenorrhea and bleeding amount, but with a similar safety profile compared with Cu-IUD.

Noble lessons from a kidney donor.

Levonorgestrel-releasing Intrauterine System Effects on Metabolic Variables in PCOS.

Molecular Systems Biology Peer Review Process File Genetic Variation in Insulin-induced Kinase Signaling Transaction Report

Factors Associated With the Use of U.S. Community-Based Palliative Care for Children With Life-Limiting or Life-Threatening Illnesses and Their Families: An Integrative Review.

Intrauterine device use is safe among nulligravidas and adolescent girls

Production of a recombinant alkane hydroxylase (AlkB2) from Alcanivoraxborkumensis

Levonorgestrel-releasing intra-uterine systems as female contraceptives

[Does desensitisation of acetylcholine receptors play a physiological role in the neuromuscular synapse?].

Early intrauterine pregnancy with an intrauterine device in place and terminated with spontaneous abortion: A case report

Levonorgestrel-Releasing Intrauterine Device Is An Efficacious Contraceptive For Women With Leiomyoma

Acoustic signal recognition with a photorefractive time-delay neural network.

Preliminary report on the use of a levonorgestrel intrauterine system for the treatment of intermenstrual bleeding due to previous cesarean delivery scar defect

One-year follow up on post-placental IUD insertion: A randomized clinical trial

Levonorgestrel Intrauterine Device Use in Overweight and Obese Women

Postplacental placement of intrauterine devices: A randomized clinical trial

Unilateral hydroureteronephrosis after introduction of a levonorgestrel-releasing intrauterine system: a case report and literature review

Newborn immunology: relevance to the clinician.

[Efficacy and Safety of Low-Dose Levonorgestrel-Releasing Intrauterine System in Chinese Women: a Multicenter, Single-Arm, Open Labeled Interventional Trial].

Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study

Towards successful user interaction with systems: focusing on user-derived gestures for smart home systems.

Bleeding Pattern Difference Between Levonorgestrel Intrauterine System and Copper Intrauterine Devices Inserted Immediately Post-Abortion: a Multicenter, Prospective, Observational Cohort Study in Chinese Women.